Navigation Links
Agendia Appoints New CEO and Supervisory Board Member
Date:10/24/2011

IRVINE, California and AMSTERDAM, October 24, 2011 /PRNewswire/ --

Agendia, an innovative molecular diagnostics company, today announced that its supervisory board of directors has appointed David Macdonald as chief executive officer. This follows the resignation of the company's co-founder and chief executive officer, Dr. Bernhard Sixt. Dr. Sixt will remain with the company in an advisory capacity. Agendia also announced the addition of Dr. Colin Goddard, executive chairman and acting CEO of privately held biotechnology firm Coferon, Inc., to its supervisory board of directors.

"On behalf of Agendia's board and all its employees, I would like to personally extend my deepest gratitude to Dr. Sixt for his leadership in making this company an internationally recognized innovator in the molecular diagnostic space," said Hessel Lindenbergh, chairman of Agendia's supervisory board. "David Macdonald is an accomplished leader in our industry and I have no doubt that under his leadership, Agendia will continue to thrive."

Macdonald has served as Agendia's COO since April 2010 and brings with him more than 25 years of international experience developing and commercializing clinical diagnostics and laboratory services for companies including Nova Biomedical, Behring Diagnostics, Nichols Institute and Quest Diagnostics. He has held CEO and COO roles for the past 18 years. He holds a Bachelor of Science degree from Northeastern University in management and finance as well as an MBA from Babson College.

Dr. Goddard served as CEO of OSI Pharmaceuticals, Inc. and as a member of the company's board of directors until it's $4 billion acquisition by Astellas Pharmaceuticals, Inc. in July of 2010. He currently serves as executive chairman and acting CEO of Coferon, Inc., a privately held biotechnology platform company. He is also a director of biotechnology companies PanOptica and Human Genome Sciences, Inc. Dr. Goddard is actively involved as an advisor to several venture capital firms and other industry groups.

"I'm pleased to welcome Collin Goddard to our supervisory board of directors. He brings with him a wealth of knowledge in the biotechnology sector and will be an asset to Agendia moving forward," said Lindenbergh.

About Agendia:

Agendia is an international molecular diagnostic company, focused on the discovery and development of tools to improve the quality of life for cancer patients, by providing healthcare professionals with critical information that enables personalized treatment.   Agendia's Symphony™ suite of breast cancer products is based on genomic analysis of an individual patient's tumor biology, providing unprecedented insight for complex treatment decisions. Symphony includes MammaPrint, the first and only FDA-cleared breast cancer recurrence assay, as well as BluePrint, a molecular subtyping assay, TargetPrint®, an ER/PR/HER2 expression assay, and TheraPrint®, a therapy selection assay. Together, these tests help physicians determine a patient's individual risk for metastasis, which patients will benefit from chemo or hormonal therapy, and which patients do not require these treatments and can instead be treated with other less arduous and costly methods. For additional information, please visit http://www.agendia.com.


'/>"/>
SOURCE Agendia B.V.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Agendia Launches TargetPrint(R) for Breast Cancer Patients
2. Agendias MammaPrint(R) Included in 2008 Dutch Institute for Healthcare Improvement CBO Guidelines
3. Agendia Supports High Profile CME Symposium and Presents Compelling Data at the 2008 San Antonio Breast Cancer Symposium
4. Agendias MammaPrint(R) Predicts Response to Neoadjuvant Chemotherapy in Breast Cancer
5. Agendias Breast Cancer Test MammaPrint(R) Identifies New Subset of Low Risk HER2+ Patients
6. Agendias Breast Cancer Recurrence Test MammaPrint Included in International St. Gallen Expert Consensus Recommendations
7. /C O R R E C T I O N -- Agendia B.V./
8. FDA Broadens Clearance for Agendias MammaPrint(R)
9. Agendia to Play Pivotal Role in ISPY-2 Trial for Breast Cancer
10. Agendia to Provide Testimony at Public Meeting on FDA Oversight of Laboratory-Developed Tests
11. Agendia Inaugurates New State-of-the-Art Genomics Laboratory in Irvine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... , Dec. 9, 2016 aTyr Pharma, Inc. (Nasdaq: ... development of Physiocrine-based therapeutics to address severe, rare diseases, today announced ... upcoming BMO Prescriptions for Success Healthcare Conference at the InterContinental Barclay ... December 14, 2016, at 4:20 p.m. ET. About ... ...
(Date:12/9/2016)... , Dec. 9, 2016 Department of Health ... regulations for medical marijuana dispensaries under Act 16 are ... , and are now available online . ... in the plan for operation; process for dispensing medical ... well as where the dispensary facilities can be located," ...
(Date:12/8/2016)... VIEW, Calif. , Dec. 8, 2016 IRIDEX ... intends to offer newly issued shares of common stock, $0.01 ... pursuant to an underwritten public offering.  The final terms of ... the time of pricing, and there can be no assurance ... IRIDEX expects to use the net proceeds it ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... December 08, 2016 , ... The West Virginia Medical Institute ... The name change aligns the entire company with its existing Quality Insights ... , “We are very proud of the achievements associated with the West Virginia ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... Donuts Franchising Company LLC, announced the first national #QuackGivesBack campaign which supported ... , “This was our first franchise-wide Quack Gives Back initiative, and ...
(Date:12/8/2016)... ... 08, 2016 , ... Mirixa Corporation , a leading ... pharmacist-delivered patient care services, has announced the promotions of Karen Litsinger to senior ... of sales. , Litsinger joined Mirixa in 2008 after serving as a ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... David ... with global law firm Greenberg Traurig, LLP, will speak at DeviceTalks West, Dec. 12, ... of the DeviceTalks series, and attorneys from the firm’s global Life Sciences & Medical ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... development continuity to its innovative Unified Instance Manager architecture, meeting the needs ... this new version optimizes the unattended auto-dialing system without agents, Presence Robodialer, ...
Breaking Medicine News(10 mins):